Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Benjamin K., Boyer, Arnaud, Ciccolini, Joseph, Barlesi, Fabrice, Wang, Kenneth, Benzekry, Sebastien, Mochel, Jonathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709425/
https://www.ncbi.nlm.nih.gov/pubmed/31004380
http://dx.doi.org/10.1002/psp4.12415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709425/
https://www.ncbi.nlm.nih.gov/pubmed/31004380
http://dx.doi.org/10.1002/psp4.12415

Ejemplares similares